Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

Oncology reports - 1 Sept 2006

Endo Katsuhiko, Sasaki Hidefumi, Yano Motoki, Kobayashi Yoshihiro, Yukiue Haruhiro, Haneda Hiroshi, Suzuki Eriko, Kawano Osamu, Fujii Yoshitaka

Abstract excerpt

Several studies have suggested that epidermal growth factor receptor (EGFR) gene mutation, EGFR gene amplification, and some other biomarkers may be predictors of gefitinib sensitivity. We analyzed EGFR mutation and EGFR copy number in 22 gefitinib-treated non-small cell lung cancer (NSCLC) cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Gene Dosage

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 16865253

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16865253-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.PMID 16865253Read ↗

Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.Semantic proximity Read ↗

Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung CancerSemantic proximity Read ↗

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.Semantic proximity Read ↗

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung CancerSemantic proximity Read ↗

Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.Semantic proximity Read ↗

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.Semantic proximity Read ↗

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas.Semantic proximity Read ↗

Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.